Patent applications published 25 May 2011
Selected patent applications from the weekly European Patents Bulletin
- Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers
Merck & Co 2323482*
- Anti-allergen combinations of calcium and lanthanum salts
Janssen Pharmaceutica 2323485*
- Methods and compsns for preventing, reducing or treating damage caused by ischaemia and ischaemia-like conditions
Nestec 2323486*
- Pseudolipid complex mixture and a skin external application compsn containing same
Amorepacific 2323616*
- Hyaluronic acid-based gels including anaesthetic agents
Allergan Industrie 2323617*
- Co-crystals and pharmaceutical formulations comprising the same
Vertex Pharmaceuticals 2323622*
- Pharmaceutical compsns
Novartis 2323623*
- Modulation of toll-like receptor 8 expression by antisense oligonucleotides
Idera Pharmaceuticals 2323624*
- New compsn for the treatment of ecchytomotic pigmentations
Biancardi, Biagio 2323625*
- Parenteral compsn comprising microspheres with a diameter between 10 and 20µm
Coretherapix Slu 2323626*
- Novel rapid-effect pharmaceutical forms and uses of resulting pharmaceutical compsns
Bionetwork 2323627*
- Carrier nanoparticles and related compsns, methods and systems
California Inst. of Technology 2323628*
- Lyophilisation above collapse
Wyeth 2323629*
- Methods, compsns and systems for local delivery of drugs
Silenseed 2323630*
- Pharmaceutical formulations of an HCV protease inhibitor in a solid molecular dispersion
Schering 2323631*
- Retard tablets containing quetiapine
Alfred E Tiefenbacher 2323632*
- Stable pharmaceutical compsn for optimised delivery of an HIV attachment inhibitor
Bristol-Myers Squibb 2323633*
- Ropinirole compsn
KRKA 2323634*
- Fibrous surface structure containing active ingredients with controlled release, use and method for production thereof
BASF 2323635*
- Chelating amphiphilic polymers
Koninklijke Philips Electronics 2323636*
- Treatment of fibrotic eye disorders
University of East Anglia 2323637*
- Methods and compsns for treating neuronal damage and modulating transient receptor potential channels
Yissum Research Development Company of the Hebrew University of Jerusalem 2323640*
- Nyasol and analogues thereof for the treatment of oestrogen receptor beta-mediated diseases
Bionovo 2323641*
- Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compsns for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders
Sooft Italia Spa 2323642*
- Compsn and method for treatment of MRSA
Ondine International 2323643*
- N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation
Novaremed 2323644*
- Use of low-dose local anaesthetic or derivatives thereof for therapy of chronic pain, especially migraine
Strackham, Klaus; Weihe, Eberhard 2323645*
- Use of steroid sulfatase inhibitors for the treatment of preterm labour
PregLem 2323646*
- Long-term treatment of symptomatic heart failure
SPA Societa’ Prodotti Antibiotici; Sixterpharma 2323647*
- Anti-arrhythmia agents, methods of their use, methods for the identification, and kits thereof
The UAB Research Foundation 2323648*
- Treating various disorders with 7,8-dihydroxyflavine and derivatives thereof
Emory University 2323649*
- Treatment for diabetes in patients inappropriate for metformin therapy
Boehringer Ingelheim International 2323650*
- Compounds for the treatment of flaviviral infections
Summit Corp 2323651*
- Treatment of lysosomal storage disorders and other proteostatic diseases
Summit Corp 2323652*
- 2-hydroxy-ethanesulphonate salt
AstraZeneca 2323653*
- Polymorphic form of granisetron hydrochloride and methods of making the same
ScinoPharm Taiwan 2323654*
- Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient
AstraZeneca 2323655*
- Pharmaceutical product comprising and a muscarinic receptor antagonist and a beta-2-adrenoreceptor agonist
AstraZeneca 2323656*
- Ophthalmic pharmaceutical compsns comprising sorafenib for the treatment of neoangiogenic pathologies of the eye
SIFI Societa’ Industria Farmaceutica Italiana 2323657*
- A new crystalline form of 4-[5-{(IR)-a-[5-(3-chlorophenyl) isoxaxol-3-yl]ethoxy]-4-methyl-4H-L, 2,4-triazol-3-yl) pyridine
AstraZeneca 2323658*